Roche / Genentech
Roche and Genentech researching their drug Obinutuzumab for the treatment of lupus nephritis. Obinutuzumab is currently being marketed to treat Chronic lymphocytic leukemia and Non-Hodgkin’s lymphoma. The drug is in phase 2 clinical trials to test if it is an effective treatment for lupus nephritis. (Up to 60% of lupus patients will develop lupus nephritis.)
Abbvie partnered with Ablynx Pharma on Vobarilizumab, aka ALX 0061 which is in phase 2 of clinical trials for SLE. The drug also showed promising results in phase 2 clinical trials for the treatment of Rheumatoid Arthritis.
Lulizumab, Lulizumab pegol, or BMS-931699 is a drug by Bristol-Myers Squibb that is being studied to treat SLE and Sjogren’s syndrome. The drug is in phase 2 of clinical trials for both lupus and Sjogren’s.
The makers of Benlysta don’t appear to have another lupus drug in the pipeline but have several clinical trials and studies focused on understanding the effectiveness of the Benlysta in lupus patients.
The well known pharmaceutical company that makes Lipitor and Celebrex is working on two early stage lupus drugs: PF-06823859 and PF-06650833. Both are early stage phase 1 drugs so there is still a lot that is unknown.
Merck recently reported positive results from its Phase 2 study of atacicept for SLE. The drug showed particularly good results in patients with high disease activity according to the study.